Fiche publication
Date publication
avril 2026
Journal
EMBO reports
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BENANI Alexandre
Tous les auteurs :
Bruse J, Marbach C, Polizzi A, Landre T, Salvi J, Alquier-Bacquie V, Chen SP, Huillet M, Rives C, Martin CMP, Perrier P, Benhamed F, Régnier M, Weger S, Naylies C, Lippi Y, Sommer C, Albin M, Lasserre F, Levade T, Schupp M, Gamet-Payrastre L, Kautz L, Loiseau N, Wahli W, Ellero-Simatos S, Cruciani-Guglielmacci C, Montagner A, Benani A, Postic C, Guillou H, Fougerat A
Lien Pubmed
Résumé
Fasting initiates a coordinated metabolic response to preserve energy balance. As glycogen stores are depleted, the body transitions to mobilizing fatty acids from adipose tissue and generating ketone bodies in the liver to sustain the function of vital organs. A network of hormonal signals and transcriptional programs coordinate these adaptations. Among these, the hepatokine fibroblast growth factor 21 (FGF21) is strongly upregulated during fasting and has been proposed as a key mediator of the fasting response. To investigate the physiological functions of FGF21, we study mice with hepatocyte-specific deletion of Fgf21. Although the liver is the primary source of circulating FGF21 during fasting, its absence in hepatocytes does not alter typical fasting-induced gene expression or key metabolic pathways such as hepatic gluconeogenesis, adipose tissue lipolysis, or ketone production. Instead, we uncover a distinct role for FGF21 in promoting protein appetite following a fast. These findings challenge the conventional view of hepatocyte-produced FGF21 as a fasting-acting hormone and reveal a more specialized function in guiding nutrient selection after energy depletion.
Référence
EMBO Rep. 2026 04 27;:
